TransEnterix (NASDAQ:TRXC) is a small medical device innovator that is making big waves in the bioscience space. The company is commercializing the stellar next-generation robotic surgery system (Senhance) that, in and of itself, has many key advantages over the multi-billion dollars da Vinci franchise of Intuitive Surgical (NASDAQ:ISRG). Sales growth have been gargantuan for a small firm: five units were transacted this year. Better yet, the company recently gained the FDA approval expansion for Senhance. In this research, we’ll explore the ramifications of this approval and to adjust our investing thesis accordingly.
Figure 1: TransEnterix stock chart (Source: StockCharts).
About The Company
As usual, we’ll briefly feature an overview of the company for new investors. Based in the Research Triangle Park NC, TransEnterix is focusing on the innovation and commercialization of medical devices to service the robotic surgical market. On Oct. 13, 2017, the FDA granted the 510(k) clearance for the marketing of the Senhance Surgical Robotic System (as shown in figure 2) for minimally invasive laparoscopic surgery. Senhance is the first new product in the (abdominal surgical robotics) market since 2000 - a year that Intuitive Surgical (NASDAQ:ISRG) gained the FDA’s nod for the da Vinci.
Figure 2: Senhance surgery (Source: TransEnterix)
Available for distribution in the US, EU and other countries like Germany, Senhance features several advantages over da Vinci, as it allows for robotic precision, haptic feedback, surgeon camera control via eye sensing, and improved ergonomics. The other key is that it’s quite cost effective and is easily integrated into the operating room.
This is a preview of the Integrated BioSci Research that was published in advanced and exclusively for subscribers of Integrated BioSci Investing. Of note, we periodically send out a completely FREE Integrated BioSci Research to people in Dr. Tran BioSci's mailing list. Be sure to sign up for our mailing list HERE to not miss a single article.
We Invite you to try our FREE 2-week trial (and, to lock in the current price to save money for the future).
Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 328% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 146% gains; Kite Pharma netted 83%; Atara Biotherapeutics (NASDAQ:ATRA) appreciated +253%. CrisprTherapeutics (NASDAQ:CRSP) garned plus 276%. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.
Notably, we’ll increase our price soon. SUBSCRIBE to our marketplace research now to lock in the current price and save money in the future. To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK the orange FOLLOW button . Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by followingthis link. If you'd like to get our other once weekly ideas sent to your mailbox, check out Dr. Tran BioSci and sign up with our mailing list.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: Our research articles are best used as starting points in your own due diligence. We are not registered investment advisors and our articles are not construed as professional investment advice. This research was a request from a subscriber of our marketplace service to assist our members in their own research. That aside, I like to inform readers of Seeking Alpha's recent policy change, in which the company implemented the paywall (not only to our articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.